Literature DB >> 3683765

Investigation of the development of tolerance to the actions of zolpidem and midazolam.

D J Sanger1, B Zivkovic.   

Abstract

It is well established that tolerance can develop very rapidly to the behaviour-suppressing effects of benzodiazepines. In previous studies, however, the depressant action of zolpidem, a novel hypnotic acting at the benzodiazepine receptor, on operant behaviour in rats was maintained after many injections. An experiment was carried out, therefore, to compare the effects of acute and chronic administration of zolpidem and midazolam. Rats were trained to press a lever in standard operant test chambers to obtain 45 mg food pellets on an FR 10 schedule. Dose-response curves were then established, before, immediately after and 4 weeks after the daily administration of midazolam (3.0 mg/kg s.c.) or zolpidem (1.0 mg/kg) for 10 days. In confirmation of previous work, marked tolerance developed to the response-rate-decreasing effect of midazolam, the dose-response curve being shifted to the right by a factor of 6 and also flattened. No significant dissipation of this tolerance occurred during a period of 4-6 weeks. In contrast, repeated administration of zolpidem produced only a small degree of tolerance, the dose-response curve being shifted by a factor of two. There was little evidence for cross tolerance between the two drugs, zolpidem-treated rats being sensitive to a dose of midazolam and midazolam-treated rats sensitive to a dose of zolpidem. Although the explanation for the development of tolerance to midazolam is unknown, these results suggest that the mechanisms of action of midazolam and zolpidem in reducing response rates are different.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3683765     DOI: 10.1016/0028-3908(87)90172-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

Review 1.  Modulation and polytypic signaling in GABAergic transmission.

Authors:  J L Schlichting
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 2.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

3.  Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance.

Authors:  J R Haigh; J P Gent; J C Garratt; T Pullar; M Feely
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

Review 4.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

5.  State-dependent effects of atypical benzodiazepine-receptor agonists.

Authors:  A Jackson
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

6.  Tolerance, cross-tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps.

Authors:  C Cohen; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

7.  Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system.

Authors:  D J Sanger; J Benavides
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.

Authors:  David J Sanger
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

10.  EEG profile of intravenous zolpidem in healthy volunteers.

Authors:  A Patat; S Trocherie; J J Thebault; P Rosenzweig; C Dubruc; G Bianchetti; L A Court; P L Morselli
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.